Who Owns Eris Lifesciences Company?

Who Owns Eris Lifesciences?

Understanding a company's ownership is key to grasping its strategic path and influence. Eris Lifesciences, an Indian pharmaceutical firm, saw a major shift with its IPO in June 2017, moving from private to public ownership.

Founded in 2007 by Amit Indubhushan Bakshi, Eris Lifesciences focuses on lifestyle disorder therapies. By March 2025, it achieved large-cap status with net sales of ₹7,053 crore and a net profit of ₹938 crore, showcasing its growth in segments like cardiovascular and anti-diabetic treatments, including products like Eris Lifesciences BCG Matrix.

Eris Lifesciences was established in 2007 by Amit Indubhushan Bakshi, an entrepreneur with extensive pharmaceutical sales experience. His vision was to concentrate on high-margin, specialized segments within India's chronic lifestyle ailments market. The company received its initial funding of ₹1.50 crore from a pharmaceutical stockist.

Founding Vision

Amit Indubhushan Bakshi founded Eris Lifesciences in 2007 with a strategic focus on high-margin, super-specialty niches within India's chronic lifestyle ailments sector.

Initial Funding

The company's inception was supported by an initial funding of ₹1.50 crore, provided by a pharmaceutical stockist.

Private Equity Investment

In 2011, ChrysCapital made a significant investment of ₹160 crore, securing a 16% stake and fueling the company's expansion.

IPO Shareholding

At the time of its Initial Public Offering in 2017, Amit Bakshi held approximately 39.97% of the company's shares, with ChrysCapital retaining 16.25%.

Early Stakeholders

Other shareholders who sold stakes during the IPO included Rakesh Shah, Rajendra Patel, Kaushal Shah, and Inderjeet Negi.

Founding Team's Focus

The founding team's strategic emphasis on chronic and acute therapies, particularly lifestyle-related disorders, guided the company's early product development and market entry.

The early ownership structure of Eris Lifesciences was significantly shaped by its founder, Amit Indubhushan Bakshi, and early investors. Bakshi, a seasoned pharmaceutical professional, initiated the company with a clear objective to target lucrative niches in the chronic lifestyle ailments market in India. The initial capital infusion of ₹1.50 crore from a pharmaceutical stockist provided the foundational support. A pivotal moment in the company's early trajectory was the 2011 investment by private equity firm ChrysCapital, which injected ₹160 crore for a 16% stake, significantly bolstering its growth capabilities. This early backing was instrumental in Eris Lifesciences' subsequent development and market presence, laying the groundwork for its future public offering. Understanding these early stakeholders is key to grasping the company's initial direction and ownership dynamics, which can be further explored in the Competitors Landscape of Eris Lifesciences.

Key Ownership Milestones

The early ownership of Eris Lifesciences was characterized by the founder's vision and strategic investments that facilitated growth.

• Founder Amit Indubhushan Bakshi's vision focused on chronic lifestyle ailments.
• Initial funding of ₹1.50 crore was secured from a pharmaceutical stockist.
• ChrysCapital invested ₹160 crore in 2011, acquiring a 16% stake.
• At the 2017 IPO, Amit Bakshi held 39.97% and ChrysCapital held 16.25%.
• Other selling shareholders included Rakesh Shah, Rajendra Patel, Kaushal Shah, and Inderjeet Negi.
• Himanshu Shah served as an Executive Director from inception until July 2019.

Complete Eris Lifesciences Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

The ownership structure of Eris Lifesciences underwent a significant transformation with its Initial Public Offering (IPO) in June 2017. This event marked its transition to a publicly traded entity, offering a substantial number of shares to the public and establishing a new phase for its ownership distribution.

As of July 2025, the promoter group holds a majority stake in Eris Lifesciences, with 54.83% of the company's shares. The founder, Amit Indubhushan Bakshi, is the primary promoter and holds a significant individual stake of 42.84%. Among institutional investors, Mutual Funds are substantial shareholders, owning 16.78% as of June 2025, showing a slight increase from the previous quarter. Foreign Institutional Investors (FIIs) hold 8.39%, while Domestic Institutional Investors (DIIs) have a smaller stake of 0.76%. Lilac Investments Limited is also a notable public shareholder with 8.79%. The retail investor segment accounts for 18.59% of the ownership. These shifts in shareholding patterns are influenced by various market activities, including trading, new share issuances, and corporate actions, reflecting the dynamic nature of Eris Lifesciences' ownership. For a deeper understanding of its early days, one can refer to the Brief History of Eris Lifesciences.

Key Ownership Details

Understanding Eris Lifesciences' ownership reveals a strong promoter presence and growing institutional interest.

• Promoter holding stands at 54.83% as of July 2025.
• Founder Amit Indubhushan Bakshi is the largest individual shareholder with 42.84%.
• Mutual Funds are significant institutional investors with 16.78% stake.
• Lilac Investments Limited holds 8.79% of the company's shares.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Board of Directors at Eris Lifesciences Ltd. is tasked with guiding the company’s strategic path, ensuring robust governance, and protecting the interests of its shareholders. As of 2024 and 2025, key individuals form this governing body, bringing diverse expertise to their roles.

The voting power within Eris Lifesciences generally adheres to the standard one-share-one-vote principle prevalent among publicly traded entities in India. This structure means that the number of shares held directly correlates with voting influence. The substantial promoter holding, notably led by Amit Bakshi, signifies a considerable impact on the company's strategic decisions and operational execution. While specific details regarding dual-class shares or special voting rights are not publicly detailed, the significant presence of both promoters and institutional investors on the board suggests a strong alignment with the interests of major shareholders, reflecting the core of Eris Lifesciences ownership.

Understanding Eris Lifesciences' Shareholding

The ownership structure of Eris Lifesciences is characterized by a strong promoter group influence. This concentration of ownership is a key factor in understanding who controls the company's direction.

• Promoter holding is a significant aspect of Eris Lifesciences ownership.
• Institutional investors also play a role in the shareholding pattern.
• The board composition reflects the influence of key stakeholders.
• Understanding the Mission, Vision & Core Values of Eris Lifesciences can provide context to their strategic direction.

Eris Lifesciences Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Recent strategic moves by Eris Lifesciences have reshaped its ownership landscape. The company has actively pursued acquisitions to broaden its market reach and product offerings, indicating a dynamic approach to growth and consolidation within the pharmaceutical sector.

Ownership trends as of June 2025 indicate subtle shifts among key investor categories. While the promoter group's stake saw a minor decrease to 54.83%, their significant control remains evident. Foreign Institutional Investors (FIIs) also experienced a slight reduction in holdings to 8.39%, despite an increase in the number of FII investors to 193. Conversely, Mutual Funds demonstrated increased confidence, raising their holdings to 16.78% with an expanded number of schemes to 23. Overall, institutional investors collectively raised their stake to 26.57%. These movements reflect evolving investor sentiment and strategic portfolio adjustments within the company.

Promoter Stake Evolution

The promoter group's shareholding slightly decreased to 54.83% as of June 2025. This sustained majority stake underscores their continued control and influence over the company's direction.

Institutional Investor Activity

Mutual Funds increased their holdings to 16.78%, while FIIs saw a marginal dip to 8.39%. The rise in the number of FII and MF investors suggests broader institutional interest.

Strategic Acquisitions Impact

Recent acquisitions, such as the 51% stake in Swiss Parenterals Ltd and the branded formulation business from Biocon Biologics, are key to expanding Eris Lifesciences' market presence, particularly in injectables.

Shareholder Returns and Equity Allotment

The company declared an interim dividend of INR 7.35 per share for FY 2024-2025. Additionally, 22,492 equity shares were allotted under the ESOP scheme on June 20, 2024, reflecting employee incentive programs.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE